Ranbaxy Laboratories has tanked as much as 35% to Rs 297 in opening deals on BSE on CNBC-TV18 reports that the US Food and Drug Administration (USFDA) issued import alert on the company’s Mohali unit.
After the problems at Paonta Sahib and Dewas, the USFDA now has a problem per se with its unit at Mohali, added report.
The stock opened at Rs 412 and has seen a combined more than one million shares changing hands on the counter on BSE and NSE.
